We are live on ! Find out more
RGNX icon

Regenxbio

178 hedge funds and large institutions have $355M invested in Regenxbio in 2026 Q1 according to their latest regulatory filings, with 33 funds opening new positions, 61 increasing their positions, 58 reducing their positions, and 26 closing their positions.

New
Increased
Maintained
Reduced
Closed

60% more call options, than puts

Call options by funds: $3.78M | Put options by funds: $2.36M

27% more first-time investments, than exits

New positions opened: 33 | Existing positions closed: 26

2% more funds holding

Funds holding: 174178 (+4)

1.24% more ownership

Funds ownership: 81.28%82.52% (+1.2%)

5% more repeat investments, than reductions

Existing positions increased: 61 | Existing positions reduced: 58

0% more funds holding in top 10

Funds holding in top 10: 22 (0)

40% less capital invested

Capital invested by funds: $593M → $355M (-$238M)

Holders
178
Holders Change
+4
Holders Change %
+2.3%
% of All Funds
2.19%
Holding in Top 10
2
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
0.02%
New
33
Increased
61
Reduced
58
Closed
26
Calls
$3.78M
Puts
$2.36M
Net Calls
+$1.42M
Net Calls Change
+$1.2M
Name Holding Trade Value Shares
Change
Change in
Stake
BlackRock
1
BlackRock
New York
$48.5M +$273K +25,997 +0.5%
RG
2
Redmile Group
California
$36.6M
JP Morgan Chase
3
JP Morgan Chase
New York
$27.1M -$732K -69,702 -2%
State Street
4
State Street
Massachusetts
$22.9M +$4.67M +444,749 +19%
Morgan Stanley
5
Morgan Stanley
New York
$17.3M +$540K +51,369 +3%
VCM
6
Vanguard Capital Management
Pennsylvania
$16.8M +$21.1M +2,007,146 New
Goldman Sachs
7
Goldman Sachs
New York
$15.4M +$568K +54,026 +3%
IHAM
8
Integral Health Asset Management
New York
$12.6M +$3.15M +300,000 +25%
Qube Research & Technologies (QRT)
9
Qube Research & Technologies (QRT)
United Kingdom
$11M +$9.12M +867,803 +196%
Geode Capital Management
10
Geode Capital Management
Massachusetts
$9.53M -$81K -7,708 -0.7%
AQR Capital Management
11
AQR Capital Management
Connecticut
$8.81M -$3.26M -310,250 -23%
VPM
12
Vanguard Portfolio Management
Pennsylvania
$8.54M +$10.7M +1,018,901 New
Dimensional Fund Advisors
13
Dimensional Fund Advisors
Texas
$8.46M +$1.12M +106,530 +12%
Assenagon Asset Management
14
Assenagon Asset Management
Luxembourg
$8.22M -$1.89M -179,769 -15%
N
15
Nuveen
North Carolina
$4.88M -$804K -76,494 -12%
Two Sigma Investments
16
Two Sigma Investments
New York
$4.65M +$4.46M +424,951 +327%
PFCS
17
Pale Fire Capital SE
Czech Republic
$4.14M -$60.9K -5,800 -1%
2L
18
22NW LP
Washington
$4.13M -$4.53M -430,920 -47%
Northern Trust
19
Northern Trust
Illinois
$3.3M +$210K +19,951 +5%
Stifel Financial
20
Stifel Financial
Missouri
$3.29M +$606K +57,723 +17%
Charles Schwab
21
Charles Schwab
California
$3.27M -$9.04K -860 -0.2%
HF
22
HRT Financial
New York
$2.94M +$542K +51,574 +17%
Bank of America
23
Bank of America
North Carolina
$2.72M +$255K +24,251 +8%
VFT
24
Vanguard Fiduciary Trust
Pennsylvania
$2.62M +$3.28M +312,064 New
Fidelity Investments
25
Fidelity Investments
Massachusetts
$2.61M +$475K +45,173 +17%

RGNX Hedge Fund Activity: Q1 2026 in Review

178 of the 8,126 institutional investors tracked by Wall St. Rank reported a position in Regenxbio (RGNX) for Q1 2026, worth a combined $355M — down 40% from $593M a quarter earlier.

Buyers outnumbered sellers: 33 funds opened new RGNX positions and 26 closed out — a net gain of 7 holders — while 61 added to existing stakes and 58 trimmed.

The largest buyer was Qube Research & Technologies (QRT), adding an estimated $9.12M. The largest seller was 22NW LP, cutting an estimated $4.53M.

  • 178 institutional investors held Regenxbio (RGNX) as of Q1 2026, up from 174 in Q4 2025.
  • Funds reported $355M of Regenxbio stock for Q1 2026, down 40% quarter-over-quarter.
  • 33 funds opened new Regenxbio positions in Q1 2026 and 26 closed out, a net change of +7 holders.
  • The largest Regenxbio buyer in Q1 2026 was Qube Research & Technologies (QRT), an estimated $9.12M added.
  • The largest Regenxbio seller in Q1 2026 was 22NW LP, an estimated $4.53M sold.

Based on aggregated 13F filings for Q1 2026.